Critical Comparison: EXACT Sciences (EXAS) & Celyad (CYAD)
EXACT Sciences (NASDAQ: EXAS) and Celyad (NASDAQ:CYAD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Institutional and Insider Ownership
82.4% of EXACT Sciences shares are owned by institutional investors. Comparatively, 3.4% of Celyad shares are owned by institutional investors. 4.0% of EXACT Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for EXACT Sciences and Celyad, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXACT Sciences presently has a consensus price target of $51.46, suggesting a potential downside of 1.68%. Celyad has a consensus price target of $74.00, suggesting a potential upside of 89.26%. Given Celyad’s stronger consensus rating and higher possible upside, analysts clearly believe Celyad is more favorable than EXACT Sciences.
Valuation & Earnings
This table compares EXACT Sciences and Celyad’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$99.38 million||63.06||-$167.21 million||($1.15)||-45.51|
|Celyad||$9.43 million||40.92||-$26.12 million||N/A||N/A|
Celyad has lower revenue, but higher earnings than EXACT Sciences.
This table compares EXACT Sciences and Celyad’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Celyad beats EXACT Sciences on 6 of the 11 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Celyad Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.